In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap ...

New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on ...

Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.

Karin Johnson, MD, says permanent daylight saving time won’t boost exercise or road safety and that sleep loss from spring ...